Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Innoscripta SE is a software company specializing in application software with a primary focus on software-as-a-service (SaaS) solutions for research and development (R&D) tax incentives and project management. Founded in 2012 and headquartered in Munich, Germany, the company has established itself as a leading provider of digital platforms that streamline R&D project workflows, facilitate time tracking, funding management, and ensure audit-proof documentation for regulatory compliance. Its technologies are particularly significant for companies seeking to optimize their utilization of government-backed R&D funding and tax credits, addressing compliance complexities and enabling efficient resource allocation across industries. The company’s integrated 360° platform leverages automation and AI-driven insights, empowering enterprises to manage various aspects of the R&D lifecycle in a single system. Innoscripta SE plays a crucial role in the information technology and software sector, supporting innovation-driven businesses throughout Germany and beyond by simplifying access to R&D funding in a rapidly evolving market exceeding 100 billion euros in value. The company is recognized for continuous innovation and a strong commitment to operational excellence and sustainable growth within the R&D tax compliance ecosystem.
€79.90
+€3.20 (+4.17%)
EOD Aug 7, 2026
Margins and capital returns are both well above average: 61.39% operating margin, ROIC at 78.82%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 59.8% YoY with margins expanding 3.7pp.
Even for strong businesses, today's 16x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
16.0x earnings, 16.3x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€118M
▲ +59.8% YoY
Net Income (TTM)
€50M
▲ +69.8% YoY
Op. Margin
63.05%
▲ +3.7pp YoY
ROIC
78.82%
▲ +5.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€49M
▲ +103.2% YoY
Op. Cash Flow (TTM)
€50M
▲ +103.7% YoY
Net Debt
-€34M
Net Cash Position
Cash & Equiv.
€47M
Continue Research
At a P/E of 16.0 and a price-to-free-cash-flow of 16.3, Innoscripta (1INN.XETR) trades below a two-stage DCF intrinsic value of about €251.14 per share, so at €79.90 the stock looks undervalued (214.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Innoscripta scores 96/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.0%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €251.14 per share for 1INN.XETR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €188.36. At today's €79.90, that puts the stock about 214.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Innoscripta scores 96 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 63.1% operating margin and a 78.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Innoscripta pays a regular dividend of about €2.40 per share per year (typically in quarterly installments), a yield of roughly 3.0% at the current price. That is a payout ratio of about 47.9% of earnings, so the dividend is well covered. Innoscripta has grown the dividend at roughly 119.1% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 1INN.XETR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 1INN.XETR currently trades below its estimated intrinsic value and scores 96/100 on quality (high-quality). It also yields about 3.0%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.